ArticleRSC advances2024
Salophen chromium(iii) complexes functionalized with pyridinium salts as catalysts for carbon dioxide cycloaddition to epoxides.
Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The catalytic properties of a series of novel chromium(iii) salophen complexes having different pyridinium chloride units (pyridinium, 2,6-dimethylpyridinium or 4-(dimethylamino)pyridinium ones) have been studied in the reaction of carbon dioxide cycloaddition to phenyl glycidyl ether. The examined complexes were found to be capable of catalyzing cycloaddition under relatively mild reaction conditions without any additional nucleophilic co-catalyst. However, their catalytic activity depended strongly on the structure and number of pyridinium salt units in the ligand molecule. The complex with a single unit of 4-(dimethylamino)pyridinium chloride turned out to be the most active among the examined ones. A TOF of up to 1480 h
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.